vs
Side-by-side financial comparison of CHIMERA INVESTMENT CORP (CIM) and Cytek Biosciences, Inc. (CTKB). Click either name above to swap in a different company.
CHIMERA INVESTMENT CORP is the larger business by last-quarter revenue ($66.2M vs $62.1M, roughly 1.1× Cytek Biosciences, Inc.). CHIMERA INVESTMENT CORP runs the higher net margin — 42.8% vs -70.9%, a 113.7% gap on every dollar of revenue. On growth, Cytek Biosciences, Inc. posted the faster year-over-year revenue change (8.1% vs 0.5%). Over the past eight quarters, Cytek Biosciences, Inc.'s revenue compounded faster (17.7% CAGR vs 0.8%).
Chimera Investment Corp is a US-based real estate investment trust (REIT) primarily investing in residential mortgage-backed securities, residential and commercial mortgage loans, and other real estate-related financial assets. It delivers sustainable risk-adjusted returns for shareholders via regular dividend distributions from its investment portfolio.
Cytek Biosciences, Inc. develops, manufactures and sells high-performance flow cytometry systems, associated reagents and analysis software. Its solutions serve life science research, clinical diagnostics and biopharmaceutical sectors, with a global customer base across North America, Europe and the Asia-Pacific region.
CIM vs CTKB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $66.2M | $62.1M |
| Net Profit | $28.3M | $-44.1M |
| Gross Margin | — | 52.9% |
| Operating Margin | 42.6% | -9.0% |
| Net Margin | 42.8% | -70.9% |
| Revenue YoY | 0.5% | 8.1% |
| Net Profit YoY | 119.3% | -557.1% |
| EPS (diluted) | $0.05 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $66.2M | $62.1M | ||
| Q3 25 | $65.0M | $52.3M | ||
| Q2 25 | $66.0M | $45.6M | ||
| Q1 25 | $69.2M | $41.5M | ||
| Q4 24 | $65.8M | $57.5M | ||
| Q3 24 | $66.5M | $51.5M | ||
| Q2 24 | $67.3M | $46.6M | ||
| Q1 24 | $65.1M | $44.9M |
| Q4 25 | $28.3M | $-44.1M | ||
| Q3 25 | $-580.0K | $-5.5M | ||
| Q2 25 | $35.5M | $-5.6M | ||
| Q1 25 | $167.3M | $-11.4M | ||
| Q4 24 | $-146.5M | $9.6M | ||
| Q3 24 | $136.5M | $941.0K | ||
| Q2 24 | $56.7M | $-10.4M | ||
| Q1 24 | $129.5M | $-6.2M |
| Q4 25 | — | 52.9% | ||
| Q3 25 | — | 52.7% | ||
| Q2 25 | — | 52.3% | ||
| Q1 25 | — | 48.6% | ||
| Q4 24 | — | 58.5% | ||
| Q3 24 | — | 56.3% | ||
| Q2 24 | — | 54.6% | ||
| Q1 24 | — | 51.3% |
| Q4 25 | 42.6% | -9.0% | ||
| Q3 25 | -0.5% | -17.6% | ||
| Q2 25 | 54.3% | -23.3% | ||
| Q1 25 | — | -36.1% | ||
| Q4 24 | -222.6% | 5.2% | ||
| Q3 24 | — | -8.2% | ||
| Q2 24 | 84.2% | -18.3% | ||
| Q1 24 | — | -23.9% |
| Q4 25 | 42.8% | -70.9% | ||
| Q3 25 | -0.9% | -10.5% | ||
| Q2 25 | 53.7% | -12.2% | ||
| Q1 25 | 241.7% | -27.5% | ||
| Q4 24 | -222.6% | 16.8% | ||
| Q3 24 | 205.4% | 1.8% | ||
| Q2 24 | 84.2% | -22.4% | ||
| Q1 24 | 198.8% | -13.8% |
| Q4 25 | $0.05 | — | ||
| Q3 25 | $-0.27 | — | ||
| Q2 25 | $0.17 | — | ||
| Q1 25 | $1.77 | — | ||
| Q4 24 | $-2.06 | — | ||
| Q3 24 | $1.39 | — | ||
| Q2 24 | $0.41 | — | ||
| Q1 24 | $1.36 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $278.6M | $90.9M |
| Total DebtLower is stronger | $251.5M | — |
| Stockholders' EquityBook value | $2.6B | $341.7M |
| Total Assets | $15.8B | $461.5M |
| Debt / EquityLower = less leverage | 0.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $278.6M | $90.9M | ||
| Q3 25 | $491.5M | $93.3M | ||
| Q2 25 | $250.2M | $75.5M | ||
| Q1 25 | $253.3M | $95.3M | ||
| Q4 24 | $84.0M | $98.7M | ||
| Q3 24 | $97.3M | $162.3M | ||
| Q2 24 | $162.3M | $177.9M | ||
| Q1 24 | $169.0M | $168.8M |
| Q4 25 | $251.5M | — | ||
| Q3 25 | $251.0M | — | ||
| Q2 25 | $135.2M | — | ||
| Q1 25 | $134.9M | — | ||
| Q4 24 | $134.6M | — | ||
| Q3 24 | $134.4M | — | ||
| Q2 24 | $62.4M | — | ||
| Q1 24 | — | — |
| Q4 25 | $2.6B | $341.7M | ||
| Q3 25 | $2.6B | $378.6M | ||
| Q2 25 | $2.6B | $377.6M | ||
| Q1 25 | $2.6B | $379.6M | ||
| Q4 24 | $2.5B | $395.7M | ||
| Q3 24 | $2.7B | $385.5M | ||
| Q2 24 | $2.6B | $389.1M | ||
| Q1 24 | $2.6B | $392.6M |
| Q4 25 | $15.8B | $461.5M | ||
| Q3 25 | $15.1B | $494.9M | ||
| Q2 25 | $14.9B | $493.3M | ||
| Q1 25 | $13.2B | $482.6M | ||
| Q4 24 | $13.1B | $499.5M | ||
| Q3 24 | $13.7B | $491.2M | ||
| Q2 24 | $13.1B | $483.7M | ||
| Q1 24 | $12.5B | $492.1M |
| Q4 25 | 0.10× | — | ||
| Q3 25 | 0.10× | — | ||
| Q2 25 | 0.05× | — | ||
| Q1 25 | 0.05× | — | ||
| Q4 24 | 0.05× | — | ||
| Q3 24 | 0.05× | — | ||
| Q2 24 | 0.02× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-248.9M | $-771.0K |
| Free Cash FlowOCF − Capex | — | $-1.8M |
| FCF MarginFCF / Revenue | — | -2.9% |
| Capex IntensityCapex / Revenue | — | 1.6% |
| Cash ConversionOCF / Net Profit | -8.78× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-8.8M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-248.9M | $-771.0K | ||
| Q3 25 | $-137.5M | $-3.9M | ||
| Q2 25 | $-7.4M | $108.0K | ||
| Q1 25 | $48.8M | $-125.0K | ||
| Q4 24 | $205.7M | $2.0M | ||
| Q3 24 | $41.4M | $13.2M | ||
| Q2 24 | $69.0M | $6.2M | ||
| Q1 24 | $57.3M | $4.0M |
| Q4 25 | — | $-1.8M | ||
| Q3 25 | — | $-4.6M | ||
| Q2 25 | — | $-1.5M | ||
| Q1 25 | — | $-974.0K | ||
| Q4 24 | — | $1.1M | ||
| Q3 24 | — | $12.2M | ||
| Q2 24 | — | $5.2M | ||
| Q1 24 | — | $3.4M |
| Q4 25 | — | -2.9% | ||
| Q3 25 | — | -8.7% | ||
| Q2 25 | — | -3.2% | ||
| Q1 25 | — | -2.3% | ||
| Q4 24 | — | 1.9% | ||
| Q3 24 | — | 23.7% | ||
| Q2 24 | — | 11.0% | ||
| Q1 24 | — | 7.6% |
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 2.0% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | 2.0% | ||
| Q2 24 | — | 2.3% | ||
| Q1 24 | — | 1.3% |
| Q4 25 | -8.78× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.21× | — | ||
| Q1 25 | 0.29× | — | ||
| Q4 24 | — | 0.21× | ||
| Q3 24 | 0.30× | 14.05× | ||
| Q2 24 | 1.22× | — | ||
| Q1 24 | 0.44× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CIM
Segment breakdown not available.
CTKB
| Products | $46.6M | 75% |
| Services | $15.5M | 25% |
